Home › Post-COVID Conditions (Long COVID) › NCT06311435

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Mentally capable of understanding and completing informed consent for the study.
* Precipitants with a lab verified diagnosis of SARS-CoV-2 or clinician note/record that an appropriate rapid test for SARS-CoV-2 was positive.
* To qualify for long COVID group participants will need to have new, persistent symptoms related to SARS-CoV-2 infection. iv. No one under the age of 18.

Exclusion Criteria:

* Subject is unable to provide informed consent.
* Primary Investigator or Sub-Investigator determines the participant's ongoing medical complaints that began after 1 November 2019 are not related to SARS-COV-2 but another disease process.

About the study

The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.

What is being tested

• RNA Biomarker Blood Test (diagnostic test)

Sponsor: MaxWell Clinic, PLC · Participants: 224 · Started: Mar 15, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06311435

Locations in the U.S.

Conditions

• Post-COVID Conditions (Long COVID)

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.